Cholesterol metabolism and therapeutic targets: Rationale for targeting multiple metabolic pathways

Clinical Cardiology

Volumn 27, Issue 6, 2004, Pages

  Turley, Stephen D ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; CHYLOMICRON; EZETIMIBE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; NICOTINIC ACID; SIMVASTATIN; VERY LOW DENSITY LIPOPROTEIN;

ATHEROGENESIS; ATHEROSCLEROSIS; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; HUMAN; HYPERCHOLESTEROLEMIA; INTESTINE ABSORPTION; LIVER METABOLISM; RACE DIFFERENCE; REVIEW; SEX DIFFERENCE;

EID: 2642561347     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.4960271506     Document Type: Review

References (47)

1. Cook RP: Distribution of sterols in organisms and in tissues. In Cholesterol. Chemistry, Biochemistry, and Pathology (Ed. Cook RP), p. 145-180. New York: Academic Press Inc., 1958
2. Vanhanen H, Kesaniemi YA, Miettinen TA: Pravastatin lowers serum cholesterol, cholesterol-precursor sterols, fecal steroids, and cholesterol absorption in man. Metabolism 1992;41:588-595
3. Sudhop T, Lütjohann D, Kodal A, Igel M, Tribble DL, Shah S, Perevozskaya I, von Bergmann K: Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 2002;106:1943-1948
4. Turley SD, Dietschy JM: The metabolism and excretion of cholesterol by the liver. In The Liver: Biology and Pathobiology (Eds. Arias IM, Jakoby WB, Popper H, Schachter D, Shafritz DA), p. 617-641. New York: Raven Press, 1988
5. Dietschy JM, Turley SD, Spady DK: Role of liver in the maintenance of cholesterol and low-density lipoprotein homeostasis in different animal species, including humans. J Lipid Res 1993;34:1637-1659
6. Grundy SM: Alternative approaches to cholesterol-lowering therapy. Am J Cardiol 2002;90:1135-1138
7. Tso P: Intestinal lipid absorption. In Physiology of the Gastrointestinal Tract (Ed. Johnson LR), p. 1867-1907. New York: Raven Press, 1994
8. Phillips C, Murugasu G, Owens D, Collins P, Johnson A, Tomkin GH: Improved metabolic control reduces the number of postprandial apolipoprotein B-48-containing particles in Type 2 diabetes. Atherosclerosis 2000;148:283-291
9. Grundy SM: Absorption and metabolism of dietary cholesterol. Ann Rev Nutr 1983;3:71-96
10. Ginsberg HN: New perspectives on atherogenesis: Role of abnormal triglyceride-rich lipoprotein metabolism. Circulation 2002;106:2137-2142
11. Mamo JCL, Proctor SD, Smith D: Retention of chylomicron remnants by arterial tissue: Importance of an efficient clearance mechanism from plasma. Atherosclerosis 1998;141:S63-S69
12. Turley SD, Dietschy JM: Sterol absorption by the small intestine. Curr Opin Lipidol 2003;14:233-240
13. Altmann SW, Davis HR Jr, Zhu L-J, Yao X, Hoos LM, Tetzloff G, Iyer SPN, Maguire M, Golovko A, Zeng M, Wang L, Murgolo N, Graziano MP: Niemann-Pick C1 like 1 protein is critical for intestinal cholesterol absorption. Science 2004;303:1201-1204
14. Berge KE, Tian H, Graf GA, Yu L, Grishin NV, Schultz J, Kwiterovich P, Shan B, Barnes R, Hobbs HH: Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science 2000;290:1771-1775
15. Lee M-H, Lu K, Hazard S, Yu H, Shulenin S, Hidaka H, Kojima H, Allikmets R, Sakuma N, Pegoraro R, Srivastava AK, Salen G, Dean M, Patel SB: Identification of a gene, ABCG5, important in the regulation of dietary cholesterol absorption. Nat Genet 2001;27:79-83
16. Connor WE, Lin DS: The intestinal absorption of dietary cholesterol by hypercholesterolemic (type II) and normocholesterolemic humans. J Clin Invest 1974;53:1062-1070
17. Nestel PJ, Havenstein N, Homma Y, Scott TW, Cook LJ: Increased sterol excretion with polyunsaturated-fat high-cholesterol diets. Metabolism 1975;24:189-198
18. Crouse JR, Grundy SM, Johnson JH: Effects of AOMA on cholesterol metabolism in man. Metabolism 1982;31:733-739
19. McMurry MP, Connor WE, Lin DS, Cerqueira MT, Connor SL: The absorption of cholesterol and the sterol balance in the Tarahumara Indians of Mexico fed cholesterol-free and high cholesterol diets. Am J Clin Nutr 1985;41:1289-1298
20. Briones ER, Steiger DL, Palumbo PJ, O'Fallon WM, Langworthy AL, Zimmerman BR, Kottke BA: Sterol excretion and cholesterol absorption in diabetics and nondiabetics with and without hyperlipidemia. Am J Clin Nutr 1986;44:353-361
21. Kesäniemi YA, Miettinen TA: Cholesterol absorption efficiency regulates plasma cholesterol level in the Finnish population. Eur J Clin Invest 1987;17:391-395
22. McNamara DJ, Kolb R, Parker TS, Batwin H, Samuel P, Brown CD, Ahrens EH Jr: Heterogeneity of cholesterol homeostasis in man. Response to changes in dietary fat quality and cholesterol quantity. J Clin Invest 1987;79:1729-1739
23. Kern F Jr: Normal plasma cholesterol in an 88-year-old man who eats 25 eggs a day. N Engl J Med 1991;324:896-899
24. Sehayek E, Nath C, Heinemann T, McGee M, Seidman CE, Samuel P, Breslow JL: Ushape relationship between change in dietary cholesterol absorption and plasma lipoprotein responsiveness and evidence for extreme interindividual variation in dietary cholesterol absorption in humans. J Lipid Res 1998;39:2415-2422
25. Bosner MS, Lange LG, Stenson WF, Ostlund RE Jr: Percent cholesterol absorption in normal women and men quantified with dual stable isotopic tracers and negative ion mass spectrometry. J Lipid Res 1999;40:302-308
26. Mittendorfer B, Ostlund RE Jr, Patterson BW, Klein S: Orlistat inhibits dietary cholesterol absorption. Obes Res 2001;9:599-604
27. Rajaratnam RA, Gylling H, Miettinen TA: Cholesterol absorption, synthesis, and fecal output in postmenopausal women with and without coronary artery disease. Arterioscler Thromb Vasc Biol 2001;21:1650-1655
28. Beynen AC, Katan MB, Van Zutphen LFM: Hypo- and hyperresponders: Individual differences in the response of serum cholesterol concentration to changes in diet. In Advances in Lipid Research (Eds. Paoletti R, Kritchevsky D), p. 115-171. New York: Academic Press, Inc., 1987
29. Schwarz M, Davis DL, Vick BR, Russell DW: Genetic analysis of intestinal cholesterol absorption in inbred mice. J Lipid Res 2001;42:1801-1811
30. Sehayek E: Genetic regulation of cholesterol absorption and plasma plant sterol levels: Commonalities and differences. J Lipid Res 2003;44:2030-2038
31. Miettinen TA, Gylling H, Strandberg T, Sarna S: Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian Simvastatin Survival Study. Finnish 4S Investigators. Br Med J 1998;316:1127-1130
32. Grundy SM, Ahrens EH, Salen G: Interruption of the enterohepatic circulation of bile acids in man: Comparative effects of cholestyramine and ileal exclusion on cholesterol metabolism. J Lab Clin Med 1971;78:94-121
33. Davidson MH, Dillon MA, Gordon B, Jones PJ, Samuels J, Weiss S, Isaacsohn J, Toth P, Burke SK: Colesevelam hydrocholoride (Cholestagel). A new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med 1999;159:1893-1900
34. Black DM: Gut-acting drugs for lowering cholesterol. Curr Atheroscler Reports 2002;4:71-75
35. Katan MB, Grundy SM, Jones P, Law M, Miettinen T, Paoletti R: Efficacy and safety of plant stanols and sterols in the management of blood cholesterol levels. Mayo Clin Proc 2003;78:965-978
36. Crouse JR, Grundy SM: Effects of sucrose polyester on cholesterol metabolism in man. Metabolism 1979;28:994-1000
37. Kesäniemi YA, Grundy SM: Turnover of low density lipoproteins during inhibition of cholesterol absorption by neomycin. Arteriosclerosis 1984;4:41-48
38. Knopp RH, Dujovne CA, LeBeaut A, Lipka LJ, Suresh R, Veltri EP: Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolaemia: A pooled analysis from two controlled phase III clinical studies. Int J Clin Pract 2003;57:363-368
39. Gagné C, Gaudet D, Bruckert E: Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation, 2002;105:2469-2475
40. Gagné C, Bays HE, Weiss SR, Mata P, Quinto K, Melino M, Cho M, Musliner TA, Gumbiner B: Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002;90:1084-1091
41. Salen G, von Bergmann K, Lütjohann D, Kwiterovich P, Kane J, Patel SB, Musliner T, Stein P, Musser B: Ezetimibe effectively reduces plasma plant sterols in patients with sitosterolemia. Circulation 2004;09:966-971
42. Bruckert E: New advances in lipid-modifying therapies for reducing cardiovascular risk. Cardiology 2002;97:59-66
43. Sudhop T, von Bergmann K: Cholesterol absorption inhibitors for the treatment of hypercholesterolaemia. Drugs 2002;62:2333-2347
44. Ginsberg HN: Treatment for patients with the metabolic syndrome. Am J Cardiol 2003;91:29E-39E
45. Turley SD, Spady DK, Dietschy JM: Identification of a metabolic difference accounting for the hyper- and hyporesponder phenotypes of cynomolgus monkey. J Lipid Res 1997;38:1598-1611
46. Davidson MH, McGarry T, Bettis R, Melani L, Lipka LJ, LeBeaut AP, Suresh R, Sun S, Veltri EP: Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002;40:2125-2134
47. Ballantyne CM, Houri J, Notarbartolo A, Melani L, Lipka LJ, Suresh R, Sun S, LeBeaut AP, Sager PT, Veltri EP: Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: A prospective, randomized, double-blind trial. Circulation 2003;107:2409-2415